title: Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.
abstract: OBJECTIVE
  Cancer is one of the most important life-threatening diseases in the world. The current efforts to combat cancer are being focused on molecular-targeted therapies. The main purpose of such approaches is based on targeting cancer cell-specific molecules to minimize toxicity for the normal cells. RON (Recepteur d'Origine Nantais) tyrosine kinase receptor is one of the promising targets in cancer-targeted therapy and drug delivery.
  
  
  METHODS
  In this review, we will summarize the available agents against extracellular domain of RON with potential antitumor activities.
  
  
  RESULTS
  The presented antibodies and antibody drug conjugates against RON in this review showed wide spectrum of in vitro and in vivo antitumor activities promising the hope for them entering the clinical trials.
  
  
  CONCLUSIONS
  Due to critical role of extracellular domain of RON in receptor activation, the development of therapeutic agents against this region could lead to fruitful outcome in cancer therapy.
authors: Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.|Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.|Students Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
authors: Omid
authors: O
authors: Zarei
authors: Molecular Therapeutics and Exploratory Research Laboratory, Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Turin, Italy.
authors: Silvia
authors: S
authors: Benvenuti
authors: Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Istanbul University, Istanbul, Turkey.
authors: Fulya
authors: F
authors: Ustun-Alkan
authors: Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. hamzehm@tbzmed.ac.ir.|Department of Medicinal Chemistry, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. hamzehm@tbzmed.ac.ir.
authors: Maryam
authors: M
authors: Hamzeh-Mivehroud
authors: Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. dastmalchi.s@tbzmed.ac.ir.|Department of Medicinal Chemistry, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. dastmalchi.s@tbzmed.ac.ir.
authors: Siavoush
authors: S
authors: Dastmalchi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D000072417:Protein Domains / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; C080835:RON protein; D020794:Receptor Protein-Tyrosine Kinases
keywords: Cancer; Drug conjugate; Monoclonal antibody; Peptide; Target therapy; Tumor; Tyrosine kinase receptor